Noxopharm Limited is an ASX-listed clinical-stage drug development company focused on the potential treatment of a wide range of cancers. The company operates under the healthcare sector and aims to create unique anti-cancer drugs. It is backed by a solid pipeline of drug candidates including Veyonda®, the first oncology pipeline product. Housed in the non-oncology subsidiary, Nyrada Inc. are four pre-clinical R and D programs.

Load More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK